EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leonhardt, S. A.
Right arrow Articles by Edwards, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leonhardt, S. A.
Right arrow Articles by Edwards, D. P.
Experimental Biology and Medicine 227:969-980 (2002)
© 2002 Society for Experimental Biology and Medicine


MINIREVIEW

Mechanism of Action of Progesterone Antagonists

Susan A. Leonhardt and Dean P. Edwards1

University of Colorado Health Sciences Center, Department of Pathology and Program in Molecular Biology, Denver, Colorado 80262

The effects of progesterone on target tissues are mediated by progesterone receptors (PRs), which belong to a family of nuclear receptors and function as ligand-activated transcription factors to regulate the expression of specific sets of target genes. Progesterone antagonists repress the biological actions of progesterone by "actively" inhibiting PR activation. This work discusses the first clinically used progesterone antagonist RU486 and closely related compounds in terms of how these compounds inhibit progesterone action through heterodimerization and competition for DNA binding and by the recruitment of corepressors to promoters of target genes to repress transcription. We discuss cellular factors that may influence the activity of these compounds, such as the availability of coactivators and corepressors and the context of specific target promoters in any given cell type. We also discuss steroidal and nonsteroidal antagonist selectivity for PR versus other steroid hormone receptors and suggest that it may be possible to develop tissue/cell specific modulators of PR.

Key Words: progesterone • progesterone receptor • steroidal antagonists • RU486, nonsteroidal antagonists




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
P. Chaudhry and E. Asselin
Resistance to chemotherapy and hormone therapy in endometrial cancer
Endocr. Relat. Cancer, June 1, 2009; 16(2): 363 - 380.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
B. T. MOE, A. B. VEREIDE, A. oRBO, R. JAeGER, and G. SAGER
Levonorgestrel, Medroxyprogesterone and Progesterone Cause a Concentration-dependent Reduction in Endometrial Cancer (Ishikawa) Cell Density, and High Concentrations of Progesterone and Mifepristone Act in Synergy
Anticancer Res, April 1, 2009; 29(4): 1047 - 1052.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
B. G. MOE, A. B. VEREIDE, A. ORBO, and G. SAGER
High Concentrations of Progesterone and Mifepristone Mutually Reinforce Cell Cycle Retardation and Induction of Apoptosis
Anticancer Res, April 1, 2009; 29(4): 1053 - 1058.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
N. Ohara, A. Morikawa, Wei Chen, Jiayin Wang, D. A. DeManno, K. Chwalisz, and T. Maruo
Comparative Effects of SPRM Asoprisnil (J867) on Proliferation, Apoptosis, and the Expression of Growth Factors in Cultured Uterine Leiomyoma Cells and Normal Myometrial Cells
Reproductive Sciences, December 1, 2007; 14(8_suppl): 20 - 27.
[Abstract] [PDF]


Home page
Hum ReprodHome page
J. D. Wren, Y. Wu, and S.-W. Guo
A system-wide analysis of differentially expressed genes in ectopic and eutopic endometrium
Hum. Reprod., August 1, 2007; 22(8): 2093 - 2102.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
K. P. Madauss, E. T. Grygielko, S.-J. Deng, A. C. Sulpizio, T. B. Stanley, C. Wu, S. A. Short, S. K. Thompson, E. L. Stewart, N. J. Laping, et al.
A Structural and in Vitro Characterization of Asoprisnil: A Selective Progesterone Receptor Modulator
Mol. Endocrinol., May 1, 2007; 21(5): 1066 - 1081.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
G. Madsen, D. A. MacIntyre, S. Mesiano, and R. Smith
Progesterone Receptor or Cytoskeletal Protein?
Reproductive Sciences, April 1, 2007; 14(3): 217 - 222.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Sasaki, N. Ohara, Q. Xu, J. Wang, D. A. DeManno, K. Chwalisz, S. Yoshida, and T. Maruo
A Novel Selective Progesterone Receptor Modulator Asoprisnil Activates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Signaling Pathway in Cultured Human Uterine Leiomyoma Cells in the Absence of Comparable Effects on Myometrial Cells
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 616 - 623.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. Wang, N. Ohara, Z. Wang, W. Chen, A. Morikawa, H. Sasaki, D. A. DeManno, K. Chwalisz, and T. Maruo
A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells
Hum. Reprod., July 1, 2006; 21(7): 1869 - 1877.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. Shao, B. Weijdegard, K. Ljungstrom, A. Friberg, C. Zhu, X. Wang, Y. Zhu, J. Fernandez-Rodriguez, E. Egecioglu, E. Rung, et al.
Nuclear progesterone receptor A and B isoforms in mouse fallopian tube and uterus: implications for expression, regulation, and cellular function
Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E59 - E72.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
W. Chen, N. Ohara, J. Wang, Q. Xu, J. Liu, A. Morikawa, H. Sasaki, S. Yoshida, D. A. Demanno, K. Chwalisz, et al.
A Novel Selective Progesterone Receptor Modulator Asoprisnil (J867) Inhibits Proliferation and Induces Apoptosis in Cultured Human Uterine Leiomyoma Cells in the Absence of Comparable Effects on Myometrial Cells
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1296 - 1304.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
J. J. Peluso, A. Pappalardo, R. Losel, and M. Wehling
Expression and Function of PAIRBP1 Within Gonadotropin-Primed Immature Rat Ovaries: PAIRBP1 Regulation of Granulosa and Luteal Cell Viability
Biol Reprod, August 1, 2005; 73(2): 261 - 270.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
K. Chwalisz, M. C. Perez, D. DeManno, C. Winkel, G. Schubert, and W. Elger
Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis
Endocr. Rev., May 1, 2005; 26(3): 423 - 438.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
N. Chabbert-Buffet, G. Meduri, P. Bouchard, and I. M. Spitz
Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications
Hum. Reprod. Update, May 1, 2005; 11(3): 293 - 307.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. L. Escudero, P. J. Boerrigter, H. J. T. C. Bennink, R. Epifanio, J. A. Horcajadas, F. Olivennes, A. Pellicer, and C. Simon
Mifepristone Is an Effective Oral Alternative for the Prevention of Premature Luteinizing Hormone Surges and/or Premature Luteinization in Women Undergoing Controlled Ovarian Hyperstimulation for in Vitro Fertilization
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2081 - 2088.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
G. V. Rayasam, C. Elbi, D. A. Walker, R. Wolford, T. M. Fletcher, D. P. Edwards, and G. L. Hager
Ligand-Specific Dynamics of the Progesterone Receptor in Living Cells and during Chromatin Remodeling In Vitro
Mol. Cell. Biol., March 15, 2005; 25(6): 2406 - 2418.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Cho, B. L. Kagan, J. A. Blackford Jr., D. Szapary, and S. S. Simons Jr.
Glucocorticoid Receptor Ligand Binding Domain Is Sufficient for the Modulation of Glucocorticoid Induction Properties by Homologous Receptors, Coactivator Transcription Intermediary Factor 2, and Ubc9
Mol. Endocrinol., February 1, 2005; 19(2): 290 - 311.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Q. Xu, S. Takekida, N. Ohara, W. Chen, R. Sitruk-Ware, E. D. B. Johansson, and T. Maruo
Progesterone Receptor Modulator CDB-2914 Down-Regulates Proliferative Cell Nuclear Antigen and Bcl-2 Protein Expression and Up-Regulates Caspase-3 and Poly(Adenosine 5'-Diphosphate-ribose) Polymerase Expression in Cultured Human Uterine Leiomyoma Cells
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 953 - 961.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
Y.-W. Jung, E.-J. Hong, K.-C. Choi, and E.-B. Jeung
Novel Progestogenic Activity of Environmental Endocrine Disruptors in the Upregulation of Calbindin-D9k in an Immature Mouse Model
Toxicol. Sci., January 1, 2005; 83(1): 78 - 88.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Kauppi, C. Jakob, M. Farnegardh, J. Yang, H. Ahola, M. Alarcon, K. Calles, O. Engstrom, J. Harlan, S. Muchmore, et al.
The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain: RU-486 INDUCES A TRANSCONFORMATION THAT LEADS TO ACTIVE ANTAGONISM
J. Biol. Chem., June 13, 2003; 278(25): 22748 - 22754.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X.-L. Zhang, D. Zhang, F. J. Michel, J. L. Blum, F. A. Simmen, and R. C. M. Simmen
Selective Interactions of Kruppel-like Factor 9/Basic Transcription Element-binding Protein with Progesterone Receptor Isoforms A and B Determine Transcriptional Activity of Progesterone-responsive Genes in Endometrial Epithelial Cells
J. Biol. Chem., June 6, 2003; 278(24): 21474 - 21482.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Experimental Biology and Medicine.